share_log

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy（納斯達克）在 StockNews.com 上獲得分析師的保持評級
kopsource ·  2022/12/27 01:21

StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

斯托克新聞網在週六上午發給投資者的一份研究報告中開始對Otmey(納斯達克：One-Get Rating)的股票進行報道。該公司對這家生物製藥公司的股票發佈了持有評級。

Separately, Piper Sandler lowered shares of Otonomy from an overweight rating to a neutral rating and dropped their price target for the company from $3.00 to $0.50 in a research note on Thursday, October 13th.

另外，派珀·桑德勒在10月13日(星期四)的一份研究報告中將Otmey的股票評級從增持下調至中性，並將該公司的目標價從3.00美元下調至0.50美元。

Get
到達
Otonomy
眼球運動
alerts:
警報：

Otonomy Price Performance

高性價比

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a market capitalization of $4.23 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 52 week low of $0.06 and a 52 week high of $2.59. The firm's 50 day moving average is $0.11 and its two-hundred day moving average is $0.68.

上週五，Otmey的股票開盤報0.07美元。該公司的市值為423萬美元，本益比為-0.10，貝塔係數為1.31。Otomy的52周低點為0.06美元，52周高位為2.59美元。該公司的50日移動均線切入位在0.11美元，200日移動均線切入位在0.68美元。

Hedge Funds Weigh In On Otonomy

對沖基金對Otmey的看法

Hedge funds have recently added to or reduced their stakes in the stock. Requisite Capital Management LLC acquired a new stake in shares of Otonomy in the third quarter valued at approximately $44,000. Two Sigma Investments LP boosted its holdings in shares of Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 80,153 shares during the period. Lynx1 Capital Management LP boosted its holdings in shares of Otonomy by 7,609.6% in the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock valued at $682,000 after acquiring an additional 2,282,880 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Otonomy in the third quarter valued at approximately $1,621,000. Finally, State Street Corp boosted its holdings in shares of Otonomy by 5.1% in the first quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock valued at $437,000 after acquiring an additional 8,839 shares during the period. 41.23% of the stock is currently owned by hedge funds and other institutional investors.
對沖基金最近增持或減持了該股。必備資本管理公司在第三季度收購了Otmey公司的新股份，價值約為4.4萬美元。Two Sigma Investments LP在第三季度增持了129.2%的Otomy股票。Two Sigma Investments LP現在擁有這家生物製藥公司142,183股票，價值42,000美元，在此期間又購買了80,153股票。Lynx1 Capital Management LP在第三季度將其持有的Otmey股票增加了7609.6%。Lynx1 Capital Management LP在此期間額外收購了2,282,880股，現在擁有這家生物製藥公司2,312,880股股票，價值682,000美元。Point72 Asset Management L.P.在第三季度收購了Otmey的新股份，價值約1,621,000美元。最後，道富銀行在第一季度增持了Otmey的股票5.1%。道富集團目前擁有182,239股這家生物製藥公司的股票，價值437,000美元，在此期間又購買了8,839股。41.23%的股票目前由對沖基金和其他機構投資者持有。

Otonomy Company Profile

Otmey公司簡介

(Get Rating)

(獲取評級)

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Otomy，Inc.是一家生物製藥公司，在美國開發神經學療法。該公司提供治療耳鳴的N-甲基-D-天冬氨酸受體拮抗劑Gacycldine的持續暴露製劑OTO-313，以及治療耳鳴的腦源性神經營養因數持續暴露製劑OTO-413，該製劑處於第二階段臨床試驗，用於修復耳蝸突觸和治療噪音中語音聽力困難。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免費獲取StockNews.com關於OTMy的研究報告(OTIC)
  • 新年值得關注的三隻醫療保健便士股
  • 西南航空公司股票，有很多值得愛的東西
  • MarketBeat：回顧一週12/19-12/23
  • 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
  • 通脹降溫，標普500指數何去何從

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收《Otmey Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Otmey及相關公司評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論